Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Nexstim

14,95 EUR

+0,34 %

5.591 følger denne virksomhed

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Investorkonsensus
Sammenligne
+0,34 %
+2,40 %
+8,73 %
+94,16 %
+89,24 %
+175,83 %
+269,59 %
+281,89 %
-97,53 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Læs mere
Markedsværdi
107,84 mio. EUR
Aktieomsætning
215,84 t EUR
P/E (adj.) (25e)
26,46
EV/EBIT (adj.) (25e)
25,71
P/B (25e)
13,68
EV/S (25e)
6,97
Udbytteafkast, % (25e)
-
Dækning
Anbefaling
Reducer
Kursmål
12.50 EUR
Opdateret
18.08.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analytiker

Seneste analyse

Seneste analyse

Udgivelse: 18.08.2025

Seneste omfattende analyse

Udgivelse: 26.06.2025

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Risiko
Forretningsrisiko
Værdiansættelsesrisiko
Lav
Høj
Alle
Analyse
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse27.10.2025, 07.00

Hospital in Finland Orders Nexstim NBS 6 System

Nexstim
Nexstim Q3'25: Steady progress during the fall
Analytikerkommentar23.10.2025, 07.01 af
Antti Siltanen

Nexstim Q3'25: Steady progress during the fall

Nexstim published its Q3’25 business update on Wednesday. The company reported that it delivered 16 systems during Q1-Q3.

Nexstim
Pressemeddelelse22.10.2025, 06.00

Nexstim Plc Business Update Q3 2025

Nexstim

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse14.10.2025, 06.00

Private Medical Center in Finland Orders Nexstim NBS 6 System

Nexstim
Nexstim received diagnostic approval also in the US
Analytikerkommentar13.10.2025, 05.57 af
Antti Siltanen

Nexstim received diagnostic approval also in the US

Nexstim announced on Friday that it had received diagnostic approval for its NBS 6 system in the United States. The news follows the recent similar MDR certification in Europe.

Nexstim
Pressemeddelelse10.10.2025, 13.00

Nexstim releases the NBS 6 for diagnostic use in the United States

Nexstim
NBS 6 diagnostic system received MDR certification in the EU as expected
Analytikerkommentar10.10.2025, 06.41 af
Antti Siltanen

NBS 6 diagnostic system received MDR certification in the EU as expected

On Thursday, Nexstim announced it had received MDR (Medical Device Regulation) certification for its NBS 6 diagnostic system. The approval enables the sale of NBS 6 in Europe with both therapeutic and diagnostic features.

Nexstim
Pressemeddelelse9.10.2025, 11.00

Nexstim Receives NBS 6 System Order from US Customer

Nexstim
Selskabsmeddelelse9.10.2025, 08.58

Correction: Insider information: Nexstim’s NBS 6 diagnostics system receives MDR certification in the EU

Nexstim
Selskabsmeddelelse9.10.2025, 08.25

Nexstim’s NBS 6 diagnostics system receives MDR certification in the EU

Nexstim
Selskabsmeddelelse8.10.2025, 06.00

Nexstim Plc: Share subscriptions based on stock options 2020 and 2023

Nexstim
Pressemeddelelse7.10.2025, 06.00

Nexstim Receives System Order from US Clinic

Nexstim
Pressemeddelelse23.9.2025, 06.15

Nexstim Receives NBS 5+ System Order from Pediatric Hospital in United States

Nexstim
Regulation of medical devices and diagnostics in Europe
Analytikerkommentar19.9.2025, 05.18 af
Antti Siltanen

Regulation of medical devices and diagnostics in Europe

The EU is the world's second largest market for medical devices after the United States. In this article, we will go through the basics of EU regulation from an investor's perspective.

BioretecAiforia TechnologiesNexstimBiohitOptomedRevenio GroupModulightDetection TechnologyNightingale HealthBittium
Pressemeddelelse16.9.2025, 06.00

Nexstim Receives NBS 5+ System Order from Therapy Customer in United States

Nexstim
Classification of medical devices and regulatory processes in the United States
Analytikerkommentar8.9.2025, 09.56 af
Antti Siltanen

Classification of medical devices and regulatory processes in the United States

We continue our series of articles focusing on Life Science investing, the first four parts of which focused on drug development. Subsequent articles will cover medical devices.

BioretecNexstimOptomedRevenio GroupModulightBittiumDetection Technology
Nexstim H1'25: Strong order book heading into next half of the year
Analyse18.8.2025, 10.06 af
Antti Siltanen

Nexstim H1'25: Strong order book heading into next half of the year

Nexstim's H1 was marked by strong revenue growth and improving profitability. Although the company missed our estimates, this was due to timing issues.

Nexstim
Selskabsmeddelelse15.8.2025, 06.00

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2025 (UNAUDITED)

Nexstim
Nexstim H1'25 preview: Profitable H1 in expectations
Analytikerkommentar13.8.2025, 06.05 af
Antti Siltanen

Nexstim H1'25 preview: Profitable H1 in expectations

We expect EBIT to turn profitable based on sales announcements, supported by a successful summer.

Nexstim
Pressemeddelelse12.8.2025, 06.00

Notice of Nexstim Plc’s Half-Year Report H1 2025

Nexstim
Forumopdateringer
Det må være en ny enhed, når den koster 330000e https://ted.europa.eu/fi/notice/-/detail/710770-2025
28.10.2025, 11.06
af Panha
26
Nexstim lige på LinkedIn; Når kirurger opererer sprogligt eloquente gliomer, står de over for et vanskeligt kompromis: at fjerne så meget af tumoren som muligt for at forbedre overlevelsestiden, men undgå permanente postoperative sprogdefekter. En nylig undersøgelse fra MD Anderson...
5.11.2025, 12.12
af Taitoo
16
https://www.linkedin.com/posts/nexstim_prof-jääskeläinen-on-navigated-rtms-for-activity-7389269889355505664-u1oW?utm_source=share&utm_medium=member_android&rcm=ACoAACrxP3sBbqmEKUCli829qTYlP-2hndfLc_Q Nexstim på LinkedIn. Case om smertebehandling præsenteres.
29.10.2025, 19.52
af Jatast
16
https://www.nexstim.com/investors/ownership-/-shareholder-register/helsinki I praksis sælger ingen. Tænk på, hvilke afkast nogle af folkene har opnået, og de letter stadig ikke på beholdningen
3.11.2025, 08.04
af Pertpit
14
Nogle nye navne er også kommet med på listen over de 100 største. Når man ser på salgssiden lige nu, kan en stigning være stejl med gode nyheder, da der ikke synes at være større salgsinteresser. Købssiden er også ret tynd, så et fald ved dårlige nyheder vil sandsynligvis også væ...
3.11.2025, 08.24
af Fin Master
9
https://www.tandfonline.com/doi/full/10.1080/14737140.2025.2583399 “Bestemmende faktorer for neuroplasticitet hos patienter med hjernetumorer: indvirkning af konnektom og kunstig intelligens. En narrativ anmeldelse” “En anmelder af dette manuskript har oplyst, at de er tidligere ...
4.11.2025, 19.53
af Jatast
8
Lad
for 5 timer siden
af Kyhnykeisari
7
Besøg forummet
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.